Effect of gender on the tolerability, safety and pharmacokinetics of clazosentan following long-term infusion

Clinical Drug Investigation

Volumn 27, Issue 11, 2007, Pages 797-802

  Van Giersbergen, Paul L M ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Clazosentan, pharmacokinetics; Endothelin A receptor antagonists, pharmacokinetics; Gender differences

Indexed keywords

AVX 034343; CLAZOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCOSE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL EXAMINATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE SEVERITY; DIZZINESS; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HUMAN; LABORATORY TEST; LONG TERM CARE; LOW DRUG DOSE; MALE; NAUSEA AND VOMITING; NORMAL HUMAN; NOSE CONGESTION; PHOTOPHOBIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECORDING; SEX DIFFERENCE; VITAL SIGN; VOLUNTEER; VOMITING;

EID: 34948901277     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727110-00006     Document Type: Article

References (12)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988 Mar; 332 (6163): 411-5
2. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Eng J Med 1993 Jun; 328 (24): 1732-9
3. Masaoka H, Suzuki R, Hirata Y, et al. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet 1989 Dec; (8676): 1402
4. Roux S, Breu V, Giller T, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997 Dec; 283 (3): 1110-8
5. Roux S, Loffler BM, Gray GA, et al. The role of endothelin in experimental cerebral vasospasm. Neurosurgery 1995 Jul; 37 (1): 78-85
6. Harrod CG, Bendok BR, Batjer HH. Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: a review. Neurosurgery 2005 Apr; 56 (4): 633-54
7. Van Giersbergen PLM, Dingemanse J. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist. Eur J Clin Pharmacol 2007 Feb; 63 (2): 151-8
8. King Jr JT. Epidemiology of aneurysmal subarachnoid hemorrhage. Neuroimaging Clin N Am 1997 Nov; 7 (4): 659-68
9. Kongable GL, Lanzino G, Germanson TP, et al. Gender-related differences in aneurysmal subarachnoid hemorrhage. J Neurosurg 1996 Jan; 84 (1): 43-8
10. Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther 2006 Jun; 110 (3): 386-414
11. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled multicenter phase IIa study. J Neurosurg 2005 Jul; 103 (1): 9-17
12. Fukuroda T, Fujikawa T, Ozaki S, et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994; 199 (3): 1461-5